Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
18 Octubre 2024 - 3:31PM
Chimerix (NASDAQ:CMRX), today announced that on October 16, 2024,
the Compensation Committee of Chimerix’s Board of Directors granted
an inducement award to a new employee of non-statutory stock
options to purchase up to a total of 130,000 shares of Chimerix’s
common stock. The Compensation Committee of Chimerix’s Board of
Directors approved the award as an inducement material to the new
employee’s employment in accordance with Nasdaq Listing rule
5635(c)(4).
The stock options have an exercise price per share equal to
Chimerix’s closing trading price as of the grant date. The stock
options have a 10-year term and will vest over four years, with
one-fourth vesting on the one-year anniversary of the date of hire
and the remaining three-fourths vesting over the following three
years in equal monthly installments. The stock options are subject
to the terms of Chimerix’s 2024 Equity Incentive Plan but were
granted outside of the 2024 Equity Incentive Plan.
Chimerix is a biopharmaceutical company with a mission to
develop medicines that meaningfully improve and extend the lives of
patients facing deadly diseases. The Company’s most advanced
clinical-stage development program, ONC201, is in development for
H3 K27M-mutant glioma. The Company is conducting Phase 1 dose
escalation studies of ONC206 to evaluate safety and PK data.
CONTACTS:
Will O’ConnorStern Investor
Relations212-362-1200ir@chimerix.comwill@sternir.com
Chimerix (NASDAQ:CMRX)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Chimerix (NASDAQ:CMRX)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024